Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 220 cancer 125 forskning & utveckling 111 hjärta/kärl 88 diabetes 59 andningsvägar 34 mage/tarm 14 neurovetenskap 12 FDA 10 onkologi 8 delårsrapport 7 seroquel 7 infektion 7 astma 7 akut kranskärlssjudom 6 medimmune 6 forskning 6 Observationsstudie 6 motavizumab 5 egfr-testning 5 naloxegol 5 ledning 5 vandetanib 5 RWE 5 influensavaccin 5 forxiga 5 bokslutsrapport 5 Tagrisso 5 lungcancer 4 antibiotika 4 olaparib 4 ledgångsreumatism 4 bristol-myers squibb 4 fostamatinib 4 tc-5214 4 karolinska institutet 4 fluenz 4 seroquel xr 4 pathos 3 crestor® 3 japan 3 subvention 3 anders ekblom 3 vimovo 3 slusg 3 gefitinib 3 selumetinib 3 antibiotikaresistens 3 produkt 3 egentlig depression 3 kroniskt obstruktiv lungsjukdom 3 osimertinib 3 CVD-REAL 3 astra tech 3 styrelsen 3 klopidogrel 2 caprelsa 2 återfall 2 fulvestrant 2 confirm 2 epanova 2 saturn 2 almedalen 2 ticagrelor 2 bydureon 2 opioider 2 individanpassad behandling 2 life science 2 benralizumab 2 entocort 2 seroquel xr (quetiapin fumarat) 2 recentin 2 astrazenca 2 axanum 2 patenttvist 2 slusg stipendium 2 kina 2 smärta 2 ardea biosciences 2 byetta 2 typ2diabetes 2 seroquel xl 2 corporate 2 registerstudie 2 tyskland 2 targacept 2 Real World evidence 2 kvartalsrapport 2 Brilique 2 acalabrutinib 2 läkemedelsförmånen 2 mdd 2 samarbete 2 monoterapi 1 den amerikanska läkemedelsmyndigheten 1 skelettmetastaser 1 roger henriksson 1 produktionsanläggning 1 gikt 1 cardiologföreningen 1 ovarian cancer 1 merck-avtal 1 savor 1 årsredovisning 2010 1 non-executive director 1 iressa 1 nytt läkemedel mot lungcancer 1 behandling lungcancer 1 målstyrt läkemedel 1 EGFR 1 nytt läkemedel lungcancer 1 cediranib 1 bevacizumab 1 scilifelab 1 yngre forskare 1 päivi tolstoy 1 tobias ankner 1 hans andersson 1 syntetisk kemi 1 torrent pharma 1 varumärkta generika 1 saxagliptin 1 blodsockerkontroll 1 blodsockerfall 1 viktökning 1 esc 1 ldl-c 1 gonorré 1 sepsis 1 livskvalitet lungcancer 1 ipass 1 lungcancersymtom 1 mcrc 1 complete response letter (crl) 1 u.s. food and drug administration (fda) 1 generiskt esomeprazolmagnesium 1 kanadensiska hälsovårdsministeriet 1 apotex inc (notice of compliance 1 noc) 1 internationell konkurrens 1 nikotinkanalsblockerare 1 läkemedel 1 DAISY 1 subventioner 1 UCR 1 zibotentan 1 biokemiska markörer 1 egfr-muterad 1 cytofab 1 azd9773 1 eurika 1 kombiglyze xr 1 klinisk forsk 1 pegasus 1 produktionschef 1 berzeliussamlingen 1 nya läkemedel 1 right honourable baroness shriti vadera 1 certriad 1 astrazeneca lund 1 arbetsmarknadsdagar 1 registreringsansökan 1 kastrationsresistent 1 fas 3-studie 1 hormonresistent 1 budesonid 1 mobil-app 1 opioidbehandling 1 nktr-118 1 forskningsportfölj 1 skatteärende 1 denosumab 1 amylin 1 patologi 1 NSCLC 1 egfr mutation 1 egfr positiv 1 komboglyze 1 caz-avi 1 hälsoekonomiska data 1 delårsrapport januari-september 2011 1 patientundersökning 1 david brennan 1 hudinfektioner 1 medicon village 1 translationell 1 illumina 1 årsredovisning 2011 1 antibiotikum 1 flumist 1 kvadrivalent 1 quetiapin fumarat 1 citizen petitions 1 renaissance 4 1 renaissance 5 1 formuleringspatent 1 citizens petition 1 prismodell 1 lesinurab 1 the medicines company 1 nda 1 amend 1 amylin pharmaceuticals 1 mdr-tb 1 mikael agaton 1 grymt fett 1 tonårshjärnan 1 per hamid ghatan 1 grymt fett en filmserie om tonårshjärnan 1 exacerbationer 1 pascal soriot 1 säsongsinfluensavaccin för barn som nässpray 1 säsongsinfluencavaccin 1 barninfluensavaccin 1 nässprayvaccin 1 influensanässpray 1 jonas bergh 1 bröstcancer utmärkelse 2012 1 sjukhusinfektioner 1 zinforo 1 mjukdelsinfektioner 1 ceftarolinfosamil 1 max planck institute 1 magnus björsne 1 per alfredsson 1 remissvar prismodell 1 pris läkemedel 1 strategiska centra 1 forsknings - och utvecklingscentra 1 bioläkemedel 1 tre strategiska centra 1 aks 1 exenatide 1 glp-1 agonister 1 cancerregister 1 svenska lungcancerstudiegruppen 1 non-small-cell lungcancer 1 motivationsstöd 1 patient websida 1 sekundärprevention 1 patientstöd 1 fluenz tetra 1 metreleptin 1 lipodystrofi 1 lesinurad 1 farxiga 1 xigduo 1 myalept 1 ann cairns 1 akuta koronara syndrom 1 metabola sjukdomar 1 immunoterapier 1 advaxis 1 sommarforskarskola 1 non-small cell lung cancer 1 astma/kol 1 gensekvensering 1 oic 1 hjärt-och kärlsjukdom 1 hjärinfarkt 1 biohub 1 bioventurehub 1 elisabeth björk 1 antaros 1 hha 1 healthy heart africa 1 världsdiabetesdagen 2014 1 moventig 1 Lynparza 1 opioidorsakad 1 pegasus-timi 1 e-brilique 1 Uppsala Clinical Research Center 1 mobiltelefonapplikation 1 SUPPORT-studien 1 ordnat införande Almedalen 1 QTERN 1 Zavicefta 1 moderna therapeutics 1 SvFP 1 kyntheum 1 brodalumab 1 Imfinzi 1 durvalumab 1 CVD-REAL Nordic 1 osimertinub 1 världsastmadagen 1 PACEHR 1 norge 1 svår astma 1 innovation 1 eu 1 sponsring 1 patent 1 produktion 1 lund 1 forskare 1 stipendier 1 usa 1 hjärtinfarkt 1 stroke 1 kol 1 influensa 1 depression 1 antidepressiva läkemedel 1 tlv 1 beslut 1 alzheimers 1 äggstockscancer 1 södertälje 1 högkostnadsskyddet 1 collaboration 1 halvårsrapport 1 forskarstipendium 1 schizofreni 1 merck 1 läkemedelsforskning 1 pfizer 1 psoriasis 1 bakterier 1 karolinska universitetssjukhuset 1 artros 1 pa 1 delårsrapport januari - mars 1 h1n1 1 r&d 1 mölndal 1 generiska läkemedel 1 typ 2-diabetes 1 styrelseordförande 1 gener 1 apollo 1 hälsoekonomi 1 halvårsresultat 1 pet 1 mrsa 1 ny indikation 1 diagnostik 1 förstoppning 1 kranskärlsjukdom 1 invasiv behandling 1 journal of clinical oncology 1 avancerad hormonkänslig bröstcancer 1 first studien 1 dapagliflozin 1 asco 1 konkurrenskraften 1 läkemedelsforskningen 1 forskarkarriärer 1 stipendieprogram 1 rosuvastatinkalcium 1 hyperkolesterolemi 1 pluto-studien 1 vimovotm 1 nsaid 1 pozen 1 sumitomo 1 american college of rheumatology 1 2009 annual scientific meeting in philadelphia 1 leif johansson 1 zactima (vandetanib) 1 toprol-xl 1 vaccinet 1 inflammation 1 jan lundberg 1 stemi 1 rosuvastatin 1 arimidex 1 anastrozol 1 atac 1 bypass 1 kolorektalcancer 1 sjukhussjuka 1 avancerad bröstcancer 1 avastin 1 kvalitetsregister 1 blodförgiftning 1 ämnesomsättningssjukdomar 1 jupiter-studien 1 ämnesomsättningssjukdomar (emdac) 1 jupiter 1 faslodex (fulvestrant) 1 Visa alla taggar
AstraZeneca to share latest data from an industry-leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA 2018

AstraZeneca to share latest data from an industry-leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA 2018

Pressmeddelanden   •   Jun 19, 2018 08:02 CEST

Key data evaluating the efficacy and safety of Farxiga (dapagliflozin) in combination with other type-2 diabetes therapies head-to-head vs. insulin or sulfonylurea Latest data from the DEPICT clinical programme evaluating Farxiga to address an unmet need for oral therapy in adult patients with type-1 diabetes

Update on Phase III clinical trials of lanabecestat for Alzheimer’s disease

Update on Phase III clinical trials of lanabecestat for Alzheimer’s disease

Pressmeddelanden   •   Jun 12, 2018 08:03 CEST

Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials

The EU approves Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer

The EU approves Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Jun 09, 2018 08:15 CEST

Today the European Commission has granted marketing authorisation for Tagrisso as monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial published in the New England Journal of Medicine.

Lynparza in combination with abiraterone delayed disease progression in metastatic castration-resistant prostate cancer

Lynparza in combination with abiraterone delayed disease progression in metastatic castration-resistant prostate cancer

Pressmeddelanden   •   Jun 05, 2018 08:00 CEST

AstraZeneca and Merck today presented data, which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care, in metastatic castration-resistant prostate cancer (mCRPC). Lynparza is being jointly developed and commercialised by AstraZeneca and MSD.

Moxetumomab pasudotox pivotal data in patients with previously-treated hairy cell leukaemia presented at the 2018 ASCO meeting

Moxetumomab pasudotox pivotal data in patients with previously-treated hairy cell leukaemia presented at the 2018 ASCO meeting

Pressmeddelanden   •   Jun 03, 2018 08:39 CEST

Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submission

Update on TERRANOVA Phase III trial for Fasenra in chronic obstructive pulmonary disease

Update on TERRANOVA Phase III trial for Fasenra in chronic obstructive pulmonary disease

Pressmeddelanden   •   Maj 30, 2018 08:04 CEST

TERRANOVA trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary disease

Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer

Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer

Pressmeddelanden   •   Maj 25, 2018 08:02 CEST

AstraZeneca and MedImmune today announced positive overall survival results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled, multi-centre trial of Imfinzi in patients with unresectable Stage III non-small cell lung cancer whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy.

AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline

AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline

Pressmeddelanden   •   Maj 24, 2018 08:02 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 1-5 June 2018, with an expanded portfolio in Oncology.

Regulatory submission in Japan for Forxiga in type-1 diabetes

Regulatory submission in Japan for Forxiga in type-1 diabetes

Pressmeddelanden   •   Maj 21, 2018 08:07 CEST

AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Forxiga (dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).

Lokelma approved in the US for the treatment of adults with hyperkalaemia

Lokelma approved in the US for the treatment of adults with hyperkalaemia

Pressmeddelanden   •   Maj 18, 2018 23:40 CEST

The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.

AstraZeneca PLC:s resultatrapport för första kvartalet 2018

AstraZeneca PLC:s resultatrapport för första kvartalet 2018

Pressmeddelanden   •   Maj 18, 2018 08:03 CEST

Bra lanseringar och resultat för våra nyare läkemedel stödjer oförändrad prognos

New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma

New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma

Pressmeddelanden   •   Maj 17, 2018 16:49 CEST

AstraZeneca today announced results from the Phase III SYGMA trials of Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma.

AstraZeneca is advancing clinical practice in respiratory medicine with new data at the American Thoracic Society 2018 International Congress

AstraZeneca is advancing clinical practice in respiratory medicine with new data at the American Thoracic Society 2018 International Congress

Pressmeddelanden   •   Maj 16, 2018 08:05 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, will present updates from its respiratory medicines and pipeline at the ATS 2018 International Congress, 18-23 May in San Diego, US. The breadth and depth of science are reflected in the 60 accepted abstracts, including five oral presentations, which focus on key areas of unmet need in asthma and COPD.

Lynparza tablets receive EU approval for the treatment of platinum-sensitive relapsed ovarian cancer

Pressmeddelanden   •   Maj 08, 2018 12:23 CEST

AstraZeneca and Merck & Co., Inc. today announced that the EMA has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy, regardless of BRCA status.

AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets

AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets

Pressmeddelanden   •   Maj 07, 2018 15:07 CEST

AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets.

Tagrisso receives positive EU CHMP opinion for 1st-line treatment of EGFR-mutated non-small cell lung cancer

Tagrisso receives positive EU CHMP opinion for 1st-line treatment of EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Apr 27, 2018 13:32 CEST

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a change to the terms of the Marketing Authorisation for Tagrisso to include the 1st-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

Ny studie: Patienter med svår astma träffar sällan en läkare trots att varannan patient har en okontrollerad sjukdom

Pressmeddelanden   •   Apr 27, 2018 08:09 CEST

Inför Världsastmadagen 1 maj: I PACEHR-studien har fler än 18,500 astmapatienter i Sverige studerats. Majoriteten hade en lindrig och medelsvår astma och 790 personer hade svår astma. Data från 36 vårdcentraler runt om i Sverige jämfördes med uppgifter från hälsoregister under åren 2006-2013. Syftet med studien var att beskriva förekomst, samsjuklighet, dödlighet och behandling av svår astma.

AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer

AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer

Pressmeddelanden   •   Apr 24, 2018 08:04 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, today announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments.

US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer

US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Apr 19, 2018 08:01 CEST

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.